TY - JOUR
T1 - Clinical features of antinuclear antibodies-negative type 1 autoimmune hepatitis
AU - Miyake, Yasuhiro
AU - Iwasaki, Yoshiaki
AU - Kobashi, Haruhiko
AU - Yasunaka, Tetsuya
AU - Ikeda, Fusao
AU - Takaki, Akinobu
AU - Okamoto, Ryoichi
AU - Takaguchi, Kouichi
AU - Ikeda, Hiroshi
AU - Makino, Yasuhiro
AU - Ando, Masaharu
AU - Sakaguchi, Kohsaku
AU - Yamamoto, Kazuhide
PY - 2009
Y1 - 2009
N2 - Aim: Antinuclear antibodies (ANA) are the main serologic markers of type 1 autoimmune hepatitis (AIH); however 20-30% of patients are negative for ANA. We assessed the clinical features of ANA-negative patients. Methods: A retrospective analysis was performed of 176 patients with type 1 AIH (153 females, median age 55 years). A diagnosis of AIH was made based on the revised scoring system proposed by the International Autoimmune Hepatitis Group. ANA titers were measured using a standard indirect immunofluorescence technique. Results: Thirty-eight patients (22%) had low titers of ANA (1:40 or 1:80), and 114 (65%) had high titers (≥1:160). Of 24 ANA-negative patients, 15 were positive for smooth muscle antibodies (SMA). Three of nine both ANA- and SMA-negative patients developed ANA during follow-up. The other six were diagnosed based on histological characteristics. Thirteen ANA-negative patients relapsed after the normalization of serum alanine aminotransferase (ALT) levels. ANA-negative patients more frequently showed acute presentation and, at presentation, had lower serum immunoglobulin G levels, higher serum levels of bilirubin and transaminase, and higher frequencies of histological acute hepatitis and zone 3 necrosis than those with high titers. However, the frequency of advanced stage of fibrosis was similar. The response to corticosteroids was not different among the three groups. Conclusions: ANA-negative type 1 AIH shows acute-onset more frequently but may include not only acute autoimmune hepatitis, but also acute exacerbation of inactive chronic disease. Regarding the diagnosis of ANA-negative AIH, the determination of ANA during follow-up and the response to immunosuppressive treatment may be helpful.
AB - Aim: Antinuclear antibodies (ANA) are the main serologic markers of type 1 autoimmune hepatitis (AIH); however 20-30% of patients are negative for ANA. We assessed the clinical features of ANA-negative patients. Methods: A retrospective analysis was performed of 176 patients with type 1 AIH (153 females, median age 55 years). A diagnosis of AIH was made based on the revised scoring system proposed by the International Autoimmune Hepatitis Group. ANA titers were measured using a standard indirect immunofluorescence technique. Results: Thirty-eight patients (22%) had low titers of ANA (1:40 or 1:80), and 114 (65%) had high titers (≥1:160). Of 24 ANA-negative patients, 15 were positive for smooth muscle antibodies (SMA). Three of nine both ANA- and SMA-negative patients developed ANA during follow-up. The other six were diagnosed based on histological characteristics. Thirteen ANA-negative patients relapsed after the normalization of serum alanine aminotransferase (ALT) levels. ANA-negative patients more frequently showed acute presentation and, at presentation, had lower serum immunoglobulin G levels, higher serum levels of bilirubin and transaminase, and higher frequencies of histological acute hepatitis and zone 3 necrosis than those with high titers. However, the frequency of advanced stage of fibrosis was similar. The response to corticosteroids was not different among the three groups. Conclusions: ANA-negative type 1 AIH shows acute-onset more frequently but may include not only acute autoimmune hepatitis, but also acute exacerbation of inactive chronic disease. Regarding the diagnosis of ANA-negative AIH, the determination of ANA during follow-up and the response to immunosuppressive treatment may be helpful.
KW - Acute hepatitis
KW - Antinuclear antibody
KW - Autoimmune hepatitis
KW - Immunoglobulin G
UR - http://www.scopus.com/inward/record.url?scp=69249223075&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=69249223075&partnerID=8YFLogxK
U2 - 10.1111/j.1872-034X.2008.00454.x
DO - 10.1111/j.1872-034X.2008.00454.x
M3 - Article
C2 - 19054143
AN - SCOPUS:69249223075
SN - 1386-6346
VL - 39
SP - 241
EP - 246
JO - Hepatology Research
JF - Hepatology Research
IS - 3
ER -